All In Biotech

Drug Trial Radar · NCT07874321

MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer

A Prospective, Open-Label, Single-Center, Multi-Cohort Phase II Study of Becotatug Vedotin (MRG003) Added to Ongoing Lenvatinib With or Without an Anti-PD-1 Antibody After Progression Following Prior Clinical Benefit in EGFR-Positive Advanced Thyroid Cancer

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Sep 20, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate whether adding MRG003 to an ongoing treatment regimen can produce confirmed tumor shrinkage in patients with EGFR-positive advanced thyroid cancer whose cancer initially benefited from that regimen and later progressed. The study will also evaluate the safety of the combinations. Cohort A will include patients with anaplastic or poorly differentiated thyroid carcinoma who previously benefited from lenvatinib plus an anti-PD-1 inhibitor and subsequently progressed. They will continue lenvatinib and the same anti-PD-1 inhibitor, with MRG003 added. Cohort B will include patients with radioactive iodine-refractory differentiated thyroid carcinoma who previously benefited from lenvatinib and subsequently progressed. They will continue lenvatinib, with MRG003 added. MRG003 will be given intravenously at 2.0 mg/kg every 3 weeks. The study plans to enroll 39 participants: 24 in Cohort A and 15 in Cohort B. The first 3 participants in each cohort will undergo an initial 6-week safety assessment before further enrollment is allowed. If additional safety assessment is needed, up to 6 participants who can be evaluated for dose-limiting toxicity will be assessed within the planned cohort enrollment. The main outcome is the proportion of patients in each cohort whose tumors shrink or disappear within 12 weeks after MRG003 starts, with the response confirmed at least 4 weeks later and by Week 18. Scans obtained before MRG003 is added provide the new baseline. Disease control is assessed at Week 12. Other response and survival outcomes are followed for up to 12 months after MRG003 starts. Safety follow-up continues during study treatment and for 90 days after the last study treatment dose, with longer follow-up of unresolved events as needed.

Conditions

  • Thyroid Cancer
  • Tumor
  • Advanced Thyroid Carcinoma

Interventions

  • Becotatug Vedotin (MRG003)Drug

    MRG003 is added at 2.0 mg/kg intravenously on Day 1 of each 3-week cycle to the ongoing treatment backbone: lenvatinib plus the same anti-PD-1 inhibitor in Cohort A, or lenvatinib in Cohort B. MRG003 continues until subsequent disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined discontinuation criterion; dose modifications follow protocol-defined safety rules. Infusion is over 60 +/- 15 minutes, with the first infusion lasting at least 60 minutes. Participants are monitored for infusion-related reactions during infusion and for at least 60 minutes afterward (at least 120 minutes after the first dose).

  • LenvatinibDrug

    Continued orally once daily in both cohorts at the tolerated dose used at progression before MRG003 addition. This is continuation of the prior treatment backbone, with protocol-defined dose interruptions, reductions, or discontinuation for safety. MRG003 is added after documented prior clinical benefit and subsequent RECIST 1.1 progression.

  • Anti-PD-1 Inhibitor (Continuation of Prior Treatment)Biological

    Cohort A only: continue the same anti-PD-1 inhibitor used with lenvatinib when prior clinical benefit and subsequent RECIST 1.1 progression occurred. The agent, dose, route, and dosing schedule follow the participant's prior regimen, with protocol-defined safety adjustments. A different anti-PD-1 inhibitor is not introduced as part of the add-on intervention. MRG003 is the only newly added anticancer agent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Confirmed Objective Response Rate Within 12 Weeks After Addition of MRG003Time frame: From the first MRG003 dose through Week 18; initial CR or PR must be documented within the first 12 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.